Notice: This company has been marked as potentially delisted and may not be actively trading. Cyclacel Pharmaceuticals (CYCCP) News Today Add Compare Share Share Headlines Stock AnalysisCompetitorsDividendHeadlinesTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Cyclacel Pharmaceuticals Exploring Alternatives, Cuts Costs to Preserve CashDecember 5, 2024 | marketwatch.comCyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating CostsDecember 5, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross ProceedsNovember 14, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross ProceedsNovember 13, 2024 | globenewswire.comCyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business UpdateNovember 12, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard RuleOctober 24, 2024 | globenewswire.comCyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR SymposiumOctober 23, 2024 | globenewswire.comCyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR SymposiumOctober 9, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 StudySeptember 25, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | globenewswire.comCyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting LetterSeptember 3, 2024 | globenewswire.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | msn.comCYCC Stock Earnings: Cyclacel Pharmaceuticals Beats EPS, Misses Revenue for Q2 2024August 15, 2024 | markets.businessinsider.comCyclacel Pharmaceuticals, Inc. (CYCC) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | seekingalpha.comCyclacel Pharmaceuticals earnings: here's what Wall Street expectsAugust 13, 2024 | markets.businessinsider.comCyclacel Pharmaceuticals to Release Second Quarter 2024 Financial ResultsAugust 7, 2024 | globenewswire.comCyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical CompositionsJune 26, 2024 | globenewswire.comCyclacel's Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual MeetingJune 4, 2024 | globenewswire.comCyclacel Pharmaceuticals Inc (CYCC) Q1 2024 Earnings Call Transcript Highlights: Navigating ...May 15, 2024 | finance.yahoo.comCyclacel Pharmaceuticals GAAP EPS of -$2.27 beats by $2.48May 14, 2024 | msn.comCyclacel Pharmaceuticals to Release First Quarter 2024 Financial ResultsMay 8, 2024 | globenewswire.comCyclacel Pharmaceuticals files to sell 15.2M shares for holdersMay 6, 2024 | msn.comCyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ RulesMay 2, 2024 | markets.businessinsider.comCyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ RulesMay 2, 2024 | globenewswire.com$8 Million Private Placement Announcement Sends Biotech FlyingApril 30, 2024 | msn.comWhy Is Cyclacel Pharmaceuticals (CYCC) Stock Up 46% Today?April 30, 2024 | investorplace.comCyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq RulesApril 30, 2024 | globenewswire.comCyclacel Pharmaceuticals Withdraws Securities Offering SEC FilingApril 30, 2024 | marketwatch.comTrading was temporarily halted for "CYCCP" at 02:04 PM with a stated reason of "LULD pause."April 24, 2024 | marketbeat.comTrading was temporarily halted for "CYCCP" at 01:04 PM with a stated reason of "LULD pause." Trading set to resume at 01:04 PM. April 24, 2024 | marketbeat.comTrading was temporarily halted for "CYCCP" at 01:04 PM with a stated reason of "LULD pause."April 10, 2024 | marketbeat.comCyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for CancerApril 1, 2024 | finance.yahoo.comCyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for CancerApril 1, 2024 | globenewswire.comCyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 19, 2024 | globenewswire.comCyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial ResultsMarch 13, 2024 | globenewswire.comTrading was temporarily halted for "CYCCP" at 03:03 PM with a stated reason of "LULD pause." Trading set to resume at 04:03 PM. March 7, 2024 | marketbeat.comCyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024March 7, 2024 | globenewswire.comCyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax CreditMarch 6, 2024 | globenewswire.comCyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor ConferenceFebruary 20, 2024 | finance.yahoo.comCyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor ConferenceFebruary 20, 2024 | globenewswire.comCyclacel Pharmaceuticals files to sell 411K shares of common stockJanuary 19, 2024 | msn.comWhy Is Cyclacel Pharmaceuticals (CYCC) Stock Down 9% Today?January 9, 2024 | investorplace.comCyclacel Pharmaceuticals announces registered direct and private placement offeringDecember 22, 2023 | msn.comCyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP DeletionsDecember 18, 2023 | finance.yahoo.comTrading was temporarily halted for "CYCCP" at 07:12 PM with a stated reason of "News pending."December 18, 2023 | marketbeat.comCyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SECNovember 30, 2023 | finance.yahoo.comCyclacel Pharmaceuticals GAAP EPS of -$0.49 misses by $0.13November 14, 2023 | msn.comCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | finance.yahoo.comCyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business UpdateNovember 13, 2023 | finance.yahoo.comTrading was temporarily halted for "CYCCP" at 12:11 PM with a stated reason of "LULD pause."November 13, 2023 | marketbeat.com Get Cyclacel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCCP and its competitors with MarketBeat's FREE daily newsletter. Email Address Your bank is lying to you. (Ad)You might think you have your money in a high-yield savings account, but do you really? The national average APY on savings is just 0.58%, but you can get up to 5.0% APY online with these accounts. View the best savings account rates here CYCCP Media Mentions By Week CYCCP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYCCP News Sentiment▼0.000.60▲Average Medical News Sentiment CYCCP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYCCP Articles This Week▼00▲CYCCP Articles Average Week Get Cyclacel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCCP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alpha Tau Medical News Today BriaCell Therapeutics News Today Fortress Biotech News Today GeoVax Labs News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CYCCP) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
